Zanubrutinib – November 2025

• Brand names:
  • Brukinsa®
• Pharmaceutical Company:
  • BEIGENE AUS PTY LTD
• Condition/Indication: Mantle cell lymphoma (MCL) Waldenstrom macroglobulinaemia (WM) Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
• Meeting Date: November 2025
• Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 513.3KB)
• Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 98.0KB)